The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Optimizing post-CAR-T monitoring and community delivery after liso-cel
Bradley Hunter, MD, Intermountain Healthcare, Salt Lake City, UT, discusses how the timing of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) after lisocabtagene maraleucel has informed CAR-T monitoring at his center. He explains that clinically stable patients can return to their referring oncologists after two weeks, supporting broader delivery of CAR-T therapy closer to home. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties worldwide. All rights are reserved.
